Results 81 to 90 of about 93,748 (310)
ESC Heart Failure, Volume 12, Issue 2, Page 888-899, April 2025.Abstract Aims Heart failure with preserved ejection fraction (HFpEF) continues to be an increasingly common health problem associated with a high mortality rate. Elevated levels of Growth differentiation factor‐15 (GDF15) and N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) are reportedly associated with poor clinical outcomes in a broad range of ...
Yoichiro Otaki +11 more
wiley +1 more source
Epidemiology of hospitalized heart failure in France based on national data over 10 years, 2012–2022
ESC Heart Failure, Volume 12, Issue 2, Page 1283-1294, April 2025.Abstract Aims We aim to describe the incidence of HF hospitalization in France in the post‐pandemic era, the prevalence of HF cases and patients' characteristics, management and outcomes while focusing on sex, age and socio‐economic differences and to analyse time‐trends between 2012 and 2022.
Valérie Olié +5 more
wiley +1 more source
Endothelial Function Is Impaired in Patients Receiving Antihypertensive Drug Treatment Regardless of Blood Pressure Level [PDF]
, 2017 Tatsuya Maruhashi +44 more
openalex +1 more source
ESC Heart Failure, EarlyView.Abstract In the 2021 European Society of Cardiology (ESC) heart failure (HF) guidelines, sodium–glucose cotransporter 2 (SGLT2) inhibitors were recommended for the prevention of HF in patients with type 2 diabetes mellitus (T2DM) and for the treatment of HF with reduced ejection fraction (HFrEF).
Marco Metra +25 more
wiley +1 more source
Utilization of antihypertensive drugs among chronic kidney disease patients: Results from the Chinese cohort study of chronic kidney disease (C‐STRIDE) [PDF]
, 2019 Bianling Liu +5 more
openalex +1 more source
Advancing cardio‐obstetric care through digital health technologies: A narrative review
ESC Heart Failure, EarlyView.Telehealth has enhanced prenatal and post‐partum care by improving access, continuity, and equity, particularly for high‐risk and underserved populations, without compromising maternal or fetal outcomes. Wearable and digital health technologies (e.g., electrocardiogram sensors, remote BP monitoring, mobile interventions) show strong potential to ...
Toluwalase Awoyemi +11 more
wiley +1 more source
ESC Heart Failure, EarlyView.Abstract Effective medications are available for the prevention of heart failure (HF). While their use is indicated in patients with risk factors, engagement and adherence among ‘at risk’ individuals is challenging, as it is with atherosclerotic heart disease prevention.
Anna Węgrzyn‐Witek +3 more
wiley +1 more source
Emerging evidence to start antihypertensive medication with low dose drug combinations
, 2021 Thomas Kahan
openalex +1 more source
ESC Heart Failure, EarlyView.Abstract Aims We have previously shown that patients who develop heart‐reactive antibodies (HRAs) de novo after a heart failure (HF) hospitalization are at increased risk of adverse outcomes, lending weight to the hypothesis that B cells may play a pivotal role in HF progression.
Niklas Beyersdorf +19 more
wiley +1 more source
Therapy gaps for patients with heart failure and reduced kidney function: A prospective cohort study
ESC Heart Failure, EarlyView.In this prospective registry of 1401 heart failure outpatients, patients with eGFR <60 mL/min/1.73m2 had lower achievement of target RASi and MRA doses, with the lowest absolute use in patients with eGFR <30. Beta blockers were consistently prescribed across all heart failure phenotypes and kidney function.
Chen Hsiang Ma +12 more
wiley +1 more source